



National  
Multiple Sclerosis  
Society

733 Third Avenue  
New York, NY 10017-3288

# Clinical Bulletin

Information for Health Professionals

## Bladder Dysfunction in Multiple Sclerosis

by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN

Effective bladder management strategies make it possible for people with multiple sclerosis (MS) to pursue daily activities of living and participate in the world of work with comfort, dignity and confidence. With appropriate diagnosis and treatment, the incidence of bladder complications is greatly diminished.

When treating people with MS, it is important to note that:

- ◆ **Bladder dysfunction is common in MS**, in people with minimal symptoms and those with major impairments.
- ◆ **Bladder symptoms may be responsible for withdrawal** from social and vocational activities. Frequency, urgency, and incontinence may negatively affect interpersonal interaction.
- ◆ **Bladder involvement may threaten the individual's health**, with complications leading to serious morbidity.
- ◆ **Bladder symptoms are often mismanaged**, precipitating such problems as acute urinary retention, damage to the detrusor (primary bladder muscle) and urinary tract infections (UTIs).

### NORMAL BLADDER FUNCTION

The bladder wall consists of three main layers: the mucosa, submucosa, and detrusor muscle. The detrusor, a thick layer of smooth muscle, expands to store urine and contracts to expel urine. Storage and emptying of the bladder are regulated by the internal and external urethral sphincters. Sphincters are normally in a closed position, needing stimulation to open. Continence depends on sphincter–detrusor coordination.

When approximately 250 to 300 cc of urine fill the bladder, the internal pressure activates stretch receptors in the bladder wall. The stretch receptors signal the nervous system, small contractile

waves occur in the detrusor muscle, and the internal urethral sphincter automatically relaxes. The external sphincter is consciously tightened and the urge to urinate becomes apparent. Voluntary voiding occurs when two actions occur simultaneously: the detrusor muscle contracts to expel the urine and the external sphincter relaxes and opens to allow the urine to pass freely into the urethra and out of the body.

## NEUROGENIC BLADDER DYSFUNCTION IN MS

The demyelination of MS interferes with signals between the bladder, the spinal cord, and brain, causing urination to become less controlled. Dysfunction may occur in the detrusor, external sphincter, or in the coordination of their functions. The detrusor can be hyperactive, signaling the urge to void at very low urinary volume, or hypoactive, allowing a dangerously large amount of urine to accumulate before signals to void are initiated.

### Storage Dysfunction

Storage dysfunction may be caused by an over-active detrusor muscle that contracts prematurely, as soon as a small amount of urine enters the bladder, continually signaling the need to void. The bladder does not fill to normal capacity, which results in the following symptoms:

- ◆ **Urgency:** inability to delay urination
- ◆ **Frequency:** need to urinate repeatedly
- ◆ **Nocturia:** need to urinate during the night
- ◆ **Incontinence:** inability to control time and place of urination

### Emptying Dysfunction

Demyelination in the spine interrupts signals to the voiding reflex, resulting in failure to empty the bladder. The bladder fills, but the spinal cord is unable to send the signal to the brain to relax the sphincter, and/or the bladder to contract adequately, causing the bladder to retain urine and sometimes fill beyond normal capacity. Emptying dysfunction can lead to:

- ◆ **Urgency**
- ◆ **Dribbling:** uncontrolled leaking of urine
- ◆ **Hesitancy:** delay in ability to urinate, though need to void is experienced
- ◆ **Incontinence**
- ◆ **Infection**

### Combined Dysfunction

Detrusor–external sphincter dyssynergia—or failure to store combined with failure to empty, often associated with high bladder (detruser) pressures, occurs as a result of the lack of coordination between muscle groups. Urine is trapped in the bladder, leading to:

- ◆ **Urgency**
- ◆ **Hesitancy**
- ◆ **Dribbling**
- ◆ **Incontinence** (detrusor hyperreflexia)
- ◆ **Infection**
- ◆ **Renal injury**

## URINARY TRACT INFECTION

People with MS who are unable to empty their bladder because of bladder emptying dysfunction increase their risk for UTI development. Retained urine may encourage the growth of bacteria and allows mineral deposits to settle and form stones that irritate bladder tissues. The symptoms of a UTI are:

- ◆ **Urgency**
- ◆ **Frequency**
- ◆ **Dysuria:** burning sensation during urination
- ◆ **Abdominal or lower back pain**
- ◆ **Fever**
- ◆ **Increased spasticity**
- ◆ **Dark, foul-smelling urine**


Because sensory loss may prevent people with MS from noticing some of these symptoms, they should pay particular attention to any significant changes in the color or smell of their urine, or any abrupt increase in other MS symptoms.

An abrupt increase in symptoms could signal a pseudoexacerbation, defined as a temporary flare-up of symptoms—unrelated to new damage in the central nervous system—which is typically caused by an elevation in core body temperature resulting from an infection, heat and/or humidity, or strenuous exercise. The elevated body temperature interferes with nerve conduction, resulting in symptoms such as muscle weakness, tingling, blurred or double vision and more spasms. The symptoms generally return to baseline without treatment once the body temperature returns to normal. Since pseudoexacerbations are common with UTIs, it is important to check for a bladder infection when a patient reports a sudden worsening of MS symptoms.

## ANALYSIS AND MANAGEMENT OF BLADDER SYMPTOMS

Obtain a detailed bladder history. Recurrent or persistent urinary symptoms require early consultation and assessment by a urologist, most appropriately one who is experienced in MS.

### Algorithm for Analysis and Management of Bladder Symptoms



Nancy Holland

## Algorithm for Analysis and Management of Bladder Symptoms (see page 4)

### Notes for the Algorithm

#### 1. Testing for UTI

- ◆ Use urinalysis/culture and sensitivity to test for UTI. Have appropriate antibiotic therapy initiated if UTI is present.

#### 2. Evaluation of post-void residual (PVR)

- ◆ Person must be well-hydrated.
- ◆ When person needs to void, have him/her urinate and measure volume.
- ◆ Measure residual volume in bladder by ultrasound or catheterization.
- ◆ Add voided and residual volumes to determine bladder capacity.

#### 3. Intervention

##### ◆ Storage dysfunction

- ◆ Capacity below 200 ml and/or residual less than 200 ml
  - ◆ Ditropan XL, Detrol, Oxytrol, and Gelnique (transdermal system), and Vesicare, Toviaz, Sanctura, Enablex (antimuscarinics) are first-line medications
  - ◆ DDAVP or desmopressin acetate, a hormone nasal spray or pill, temporarily reduces amount of urine produced, allowing more restful sleep
  - ◆ Pelvic floor exercises
  - ◆ Behavioral techniques—limiting caffeine, maintaining adequate fluid intake during day
  - ◆ Absorbent pads (men and women) and for men a condom-like sheath that connects to drainage
  - ◆ Assess mobility issues (proximity to toilet)

##### ◆ Emptying dysfunction

- ◆ Residual greater than 200 ml
  - ◆ Intermittent self catheterization (ISC)
  - ◆ Dietary changes to increase acidifying urine
  - ◆ Assess mobility issues (proximity to toilet)
  - ◆ Antispasmodic medications, such as Lioresal or Zanaflex
  - ◆ Flomax, Hytrin, Cardura, Rapaflo, uroxatrol, Minipress (sympatholytics) that increase urine flow

#### ◆ **Combined or detrusor–external sphincter dyssynergia (DESD)**

- ◆ Residual greater than 200 ml
- ◆ Symptoms persist despite intermittent catheterization
  - ◆ Intermittent catheterization
  - ◆ Anticholinergic medications, e.g. Detrol
  - ◆ Antispasmodic medications, such as Lioresal, Zanaflex
  - ◆ Sympatholytics, e.g.: Flomax, or Hytrin to promote urine flow
  - ◆ Botox or onabotulinumtoxinA, injected into the bladder (detrusor) wall has been FDA approved to treat urinary incontinence.

#### **4. Urologic consultation**

- ◆ Inability to relieve symptoms by following these protocols requires urologic consultation.
- ◆ Additional diagnostic measures may be needed: ultrasound, radioisotope renal scan, computerized tomography intravenous pyelogram (CTIVP), urodynamic studies, cystoscopy.

## **UROLOGIC HEALTH**

The person with MS and urinary dysfunction may become socially isolated due to fear of bladder difficulties such as incontinence. A thorough assessment and evaluation by the healthcare practitioner is imperative in discerning problems that may be compromising quality of life. It is imperative to re-assess symptoms and repeat tests such as PVR.

Recognition of symptoms suggestive of neurogenic bladder dysfunction, and active participation in assessment, management and patient teaching in this area, are important nursing responsibilities within a comprehensive team approach.

## **RECOMMENDED RESOURCES**

### **Readings**

De Seze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: Review of the literature and proposal of management guidelines. *Multiple Sclerosis* 2007 Mar; 13:915.

Halper J, Holland NJ (eds). *Comprehensive Nursing Care in Multiple Sclerosis* (3rd ed). New York: Demos Medical Publishing, 2011.

Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. *J Urol* 1999 Mar; 161(3):743–757.

Litwiller SE, Kalota SJ. Surgical management of bladder dysfunction in multiple sclerosis. *Clinical Bulletin of the National Multiple Sclerosis Society*, 2012.

Kalski V, Fowler CJ. Therapy insight: Bladder dysfunction associated with multiple sclerosis. *Nature Clinical Practice Urology* 2005 Oct; 2(10):492–501.

Schapiro RT. *Managing the Symptoms of Multiple Sclerosis* (5th ed). New York: Demos Medical Publishing, 2007.

## **Organizations**

National Association For Continence  
1-800-BLADDER  
[www.nafc.org](http://www.nafc.org)

With grateful acknowledgement of the review, update and editing services provided by Susan J. Kalota, MD.

The National Multiple Sclerosis Society acknowledges Teva Neuroscience and Novartis for their educational grant support of this bulletin.